A major metabolite of aceclofenac, 4'-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and pro-stromelysin- 1/proMMP-3 by human rheumatoid synovial cells

Inflammation Research

Volumn 49, Issue 3, 2000, Pages 133-138

  Yamazaki, R ^a   Kawai, S ^b   Mizushima, Y ^b   Matsuzaki, T ^a   Hashimoto, S ^a   Yokokura, T ^a   Ito, A ^c  

^a YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

4' Hydroxy aceclofenac; Aceclofenac; Pro matrix metalloproteinase 3; Pro matrix metalloproteinase 1; Rheumatoid synovial cell

Indexed keywords

4' HYDROXY ACECLOFENAC; ACECLOFENAC; ANTIINFLAMMATORY AGENT; COLLAGENASE; DEXAMETHASONE; DICLOFENAC; DRUG METABOLITE; INDOMETACIN; PROCOLLAGENASE; STROMELYSIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; PROSTAGLANDIN SYNTHESIS; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

EID: 0034075070     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050571     Document Type: Article

References (31)

1. [1] Manicourt D-H, Fujimoto N, Obata K, Thonar EJ-MA. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 1031-9.
2. [2] Sasaki S, Iwata H, Ishiguro N, Obata T, Miura T. Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 1994; 13: 228-33.
3. [3] Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 969-75.
4. [4] Dayer J-M, Krane SM, Russell RGG, Robinson DR. Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc Natl Acad Sci USA 1976; 73: 945-9.
5. [5] Okada Y, Nagase H, Harris ED Jr. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components: Purification and characterization. J Biol Chem 1986; 261: 14245-55.
6. [6] Okada Y, Morodomi T, Enghild JJ, Suzuki K, Yasui A, Nakanishi I, Salvesen G, Nagase H. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts: Purification and activation of the precursor and enzymic properties. Eur J Biochem 1990; 194: 721-30.
7. [7] Okada Y, Nagase H, Harris EDJr. Matrix metalloproteinases 1, 2, and 3 from rheumatoid synovial cells are sufficient to destroy joints. J Rheumatol 1987; 14: 41-2.
8. [8] Osthues A, Knäuper V, Oberhoff R, Reinke H, Tschesche H. Isolation and characterization of tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) from human rheumatoid synovial fluid. FEES Lett 1992; 296: 16-20.
9. [9] Dean DD, Martel-Pelletier J, Pelletier J-P, Howell DS, Woessner JF Jr. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989; 84: 678-85.
10. [10] Grau M, Guasch J, Montero JL, Felipe A, Carrasco E, Juliá S. Pharmacology of the potent new non-steroidal anti-inflammatory agent aceclofenac. Arzneim-Forsch 1991; 41: 1265-76.
11. [11] Ballesteros R, Ansoleaga JJ, Tapounet R. The efficacy and tolerance of aceclofenac in rheumatoid arthritis: A double-blind study v. placebo. Clin Trials J 1990; 27: 12-9.
12. [12] Ward DE, Veys EM, Bowdler JM, Roma J. Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Clin Rheumatol 1995; 14: 656-62.
13. 2-prostaglandin levels in synovial fluid and in serum. Clin Trials J 1988; 25: 144-51.
14. [14] Gonzalez E, de la Cruz C, de Nicolas R, Egido J, Herrero-Beaumont G. Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions 1994; 41: 171-8.
15. 2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmacol 1997; 329: 181-7.
16. [16] Yamazaki R, Kawai S, Matsumoto T, Matsuzaki T, Hashimoto S, Yokokura T, et al. Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells. J Pharmacol Exp Ther 1999; 289: 676-81.
17. [17] Dingle JT. The effect of NSAID on human articular cartilage glycos-aminoglycan synthesis. Eur J Rheumatol Inflamm 1996; 16:47-52.
18. [18] Dingle JT, Parker M. NSAID stimulation of human cartilage matrix synthesis: A study of the mechanism of action of aceclofenac. Clin Drug Invest 1997; 14: 353-62.
19. [19] Kenneth D, Brandt MD. Effects of nonsteroidal anti-inflammatory drugs on chondrocyte metabolism in vitro and in vivo. Am J Med 1987; 83: 29-34.
20. [20] Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
21. [21] Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
22. [22] Takahashi S, Ito A, Nagino M, Mori Y, Xie B, Nagase H. Cyclic adenosine 3′,5′-monophosphate suppresses interleukin 1-induced synthesis of matrix metalloproteinases but not of tissue inhibitor of metalloproteinases in human uterine cervical fibroblasts. J Biol Chem 1991; 266: 19894-9.
23. 2 production by human synovial cells. J Clin Invest 1986; 77: 645-8.
24. [24] Bort R, Ponsoda X, Carrasco E, Gómez-Lechón MJ, Castell JV. Metabolism of aceclofenac in humans. Drug Metab Dispos 1996; 24:834-41.
25. [25] Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231: 232-5.
26. [26] Frisch SM, Ruley HE. Transcription from the stromelysin promoter is induced by interleukin-1 and repressed by dexamethasone. J Biol Chem 1987; 262: 16300-4.
27. [27] Case JP, Lafyatis R, Kumkumian GK, Remmers EF, Wilder RL. IL-1 regulation of transin/stromelysin transcription in rheumatoid synovial fibroblasts appears to involve two antagonistic transduction pathways, an inhibitory, prostaglandin-dependent pathway mediated by cAMP, and a stimulatory, protein kinase C-dependent pathway. J Immunol 1990; 145: 3755-61.
28. [28] Salvatori R, Guidon PT Jr, Rapuano BE, Bockman RS. Prostaglandin E, inhibits collagenase gene expression in rabbit synoviocytes and human fibroblasts. Endocrinology 1992; 131: 21-8.
29. [29] Yanagawa A, Kanemitsu K, Kawai S, Hoshi K, Shimada J, Mizushima Y. Phase I clinical trial of aceclofenac: A placebo controlled double blind study (Abstract). XVIIIth ILAR Congress of Rheumatology 491, Barcelona, Spain, July 4-10, 1993.
30. [30] Yin M-J, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IΚB kinase-β. Nature 1998; 396: 77-80.
31. [31] Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-6.